Printer Friendly

New drugs for TB.

New drugs, but also shorter, better-tolerated regimens are needed to tackle the high global burden of tuberculosis complicated by drug resistance and retroviral disease. This study, published in The Lancet, investigated new multiple-agent combinations over the first 14 days of treatment to assess their suitability for future development.

In this prospective, randomised, early bactericidal activity (EBA) study, treatmentnaive, drug-susceptible patients with uncomplicated pulmonary tuberculosis were admitted to hospitals in Cape Town, South Africa, between 7 October 2010 and 19 August 2011. Patients were randomised centrally by computer-generated randomisation sequence to receive bedaquiline, bedaquiline-pyrazinamide, PA-824-pyrazinamide, bedaquiline-PA-824, PA-824-moxifloxacinpyrazinamide, or unmasked standard antituberculosis treatment as positive control. The primary outcome was the 14-day EBA assessed in a central laboratory from the daily fall in colony-forming units (CFU) of M. tuberculosis per milliliter of sputum in daily overnight sputum collections. Clinical staff were partially masked but laboratory personnel were fully masked.

The mean 14-day EBA of PA-824-moxifloxacin-pyrazinamide (n=13; 0.233 [SD 0.128]) was significantly higher than that of bedaquiline (14; 0.061 [0.068]), bedaquiline-pyrazinamide (15; 0.131 [0.102]), bedaquiline-PA-824 (14; 0.114 [0.050]), but not PA-824-pyrazinamide (14; 0.154 [0.040]), and comparable with that of standard treatment (10; 0.140 [0.094]). Treatments were well tolerated and appeared safe. One patient on PA-824-moxifloxacin-pyrazinamide was withdrawn because of corrected QT interval changes exceeding criteria pre-specified in the protocol.

PA-824-moxifloxacin-pyrazinamide is potentially suitable for treating drug-sensitive and multidrug-resistant tuberculosis. Multiagent EBA studies can contribute to reducing the time needed to develop new antituberculosis regimens.

Diacon AH, et al. The Lancet, Early Online Publication,

23 July 2012. [http://dx.doi.org/10.1016/S0140-6736(12)61080-0]
COPYRIGHT 2012 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Abstracts
Publication:CME: Your SA Journal of CPD
Date:Aug 1, 2012
Words:275
Previous Article:Acute coronary syndrome due to coronary vasospasm associated with thyrotoxicosis.
Next Article:Walking speed and hypertension in older adults.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters